Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients
Three-year median follow-up data demonstrate significantly improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival with adjuvant Opdivo compared to placeboRandomized patients who received Opdivo after radical surgery remaine...